吉利德HIV鸡尾酒疗法获FDA批准,年销售超10亿美元指日可待

2016-03-08 佚名 不详

吉利德公司HIV联合治疗方法得到FDA批准,这为吉利德公司在该治疗领域取得领袖地位奠定了一块基石。 此次获批的新药,名为Odefsey,是恩曲他滨(商品名Emtriva)、利匹韦林(强生公司,商品名为Edurant)、Tenofoviral afenamide(简写为TAF,是替诺福韦【商品名Viread】的加强版)的复方药物。这种药物获批治疗12岁及年龄更大患者的I型HIV病毒感染。I型H

吉利德公司HIV联合治疗方法得到FDA批准,这为吉利德公司在该治疗领域取得领袖地位奠定了一块基石。

此次获批的新药,名为Odefsey,是恩曲他滨(商品名Emtriva)、利匹韦林(强生公司,商品名为Edurant)、Tenofoviral afenamide(简写为TAF,是替诺福韦【商品名Viread】的加强版)的复方药物。这种药物获批治疗12岁及年龄更大患者的I型HIV病毒感染。I型HIV也是最常感染的HIV病毒类型。

根据汤森路透的预测,吉利德的这种新药Odefsey有望在2020年达到销售高峰,为16亿美元。这也是第2个通过FDA批准的包括TAF在内的鸡尾酒疗法。第1个是去年11月获批的Genvoya,是TAF、Tybost、Emtriva和Vitekta的复方药物。

吉利德能够如此快速上市,得益于FDA的快速通道,使10个月审批期减少到6个月。吉利德为此付给Knight Therapeutics1.25亿美元。

除了Odefsey,吉利德同时在开发包括TAF和Emtriva的复方药物。汤森路透估计此药的销售高峰为每年20亿美元。

吉利德面临的挑战越来越大。其竞争者包括合作者强生公司、合资企业ViiV Healthcare(葛兰素史克、辉瑞和Shionogi的合资公司)。每个竞争对手都在探寻安全性更高的HIV治疗药物组合,尽力抢占艾滋病治疗领域更大的市场份额。Odefsey顺利获批,为吉利德的霸主地位奠定了基础,在这场竞争中无疑已经取得先手。

原文出处:Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
    2016-06-21 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
    2016-03-10 qblt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
    2016-03-09 Dr.LV

    都是利益集团

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
    2016-03-09 sillywu

    HIV挣钱,丧心病狂

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1839409, encodeId=5bb018394099e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Jun 21 22:08:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687262, encodeId=cc7a168e2627a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Wed Aug 17 05:08:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542999, encodeId=bc32154299988, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574800, encodeId=988c15e4800e5, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Mar 10 07:08:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68245, encodeId=788668245e3, content=都是利益集团, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUNfdk68bHutYruGyxbKDzPWH3agcmId19Yf94FiapyicN0LTg0jykhqIhjPQVdR08FGR399rBpZIg/132, createdBy=feae1624323, createdName=Dr.LV, createdTime=Wed Mar 09 08:27:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68236, encodeId=52fb682369c, content=HIV挣钱,丧心病狂, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYZTmbW36JHpvHcnIog7VbWIQjibo1kwuH9obXRJJtqHn1hYHHLG0DpIMIBVFPhBBpQOJWDk1rbib2Y/0, createdBy=d27274268, createdName=sillywu, createdTime=Wed Mar 09 06:06:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68224, encodeId=2a70682246e, content=愿HIV感染者越来越少,珍爱生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Tue Mar 08 22:39:00 CST 2016, time=2016-03-08, status=1, ipAttribution=)]
    2016-03-08 layyjiangli

    愿HIV感染者越来越少,珍爱生命

    0

相关资讯

吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格,将极大简化丙肝临床治疗

丙肝巨头吉利德(Gilead)正在开发的一款泛基因型丙肝鸡尾酒疗法SOF/VEL(sofosbuvir/velpatasvir)近日在美国监管方面传来喜讯,FDA已授予该鸡尾酒疗法治疗全部6种基因型丙肝的优先审查资格,其审查周期将从常规的10个月缩短至6个月,有望使这款泛基因型丙肝鸡尾酒提前上市,造福美国广大丙肝群体。 SOF/VEL是一种日服一次的泛基因型丙肝鸡尾酒疗法,开发用于全部6种基因型

国纳税人炮轰,吉利德公司94500美元的天价丙肝新复方制剂

曾经被视作天价药物的吉利德公司一个疗程84000美元的丙肝治疗药物索菲布韦(Sovaldi),已经被新的药物取代。这就是吉利德公司于10月10日刚获得FDA批准的全口服丙肝新复方制剂Harvoni,该药物一个疗程的费用高达94500美元。 Harvoni由NS5A抑制剂ledipasvir和索菲布韦(Sovaldi)组成。其中索菲布韦(Sovaldi)已经成为销售增长最快的药物,并达到了重磅

丙肝治疗药物专利因缺乏创新性和创造性步骤在印度遭拒

印度专利管理局驳回了吉利德公司治疗丙肝的药物的专利申请,此举受到仿制药支持者的欢迎,因为这是一种极大降低丙肝治疗成本的方式。过去一年,丙肝见证了极昂贵的药物的出现。印度专利管理局的决定表明如果专利申请没有充足的新颖性并缺乏创造性步骤,印度法律条款将禁止授予专利。 驳回裁定称,丙肝是流行病,影响了全世界1.7亿人口,印度就有1800万。其他来源显示的数据更高。 驳回裁定称医药获取及知识组织(I-MA

EMA正式受理吉利德三合一艾滋病新药上市申请

吉利德(Gilead)近日宣布,欧洲药品管理局(EMA)已正式受理三合一HIV复方单片R/F/TAF(利匹韦林/恩曲他滨/替诺福韦,25mg/200mg/25mg)的上市许可申请(MAA),这也标志着吉利德基于TAF开发的第3款产品进入监管审查阶段,另2种产品分别为二合一(F/TAF)和四合一(E/C/F/TAF)复方新药。除此之外,吉利德还在研发另一款四合一复方产品D/C/F/TAF。 R/F

美国人民愤怒了——吉利德天价丙肝药Sovaldi印度售价仅1%

吉利德(Gilead)丙肝明星药物Sovaldi在2014上半年的销售额达到了惊人的58亿美元。该药于2013年12月在美国上市,自诞生之日起便成为行业关注的焦点,其84000美元/疗程(1000美元/片)的定价也饱受各方争议。美国众议院、患者维权组织等机构曾强烈呼吁Sovaldi降价,而吉利德则坚持不降,并称从长远来看,该药将为纳税人节省大笔开支。然而,昨日接受印度时报采访时,吉利德表示,将

喜大普奔!吉利德丙肝鸡尾酒Harvoni获FDA批准!

喜大普奔!吉利德丙肝鸡尾酒Harvoni获FDA批准!吉利德(Gilead)是丙型肝炎领域的领军人物,明星药物Sovaldi销售已突破70亿美元。新一代丙肝鸡尾酒疗法Harvoni爆出好消息,该药已获FDA批准,是首个每日一次的复方单片鸡尾酒疗法,完全消除了利巴韦林(RBV)和注射药物干扰素。业界预测,该药年销售峰值将超过Sovaldi,达到100亿美元,同时将成为丙肝临床治疗的金标准。此外,